An Open-label, Single-centre, 3-way Single Dose Crossover Study to Assess the Relative Bioavailability After Oral Administration of a Tablet Variant of AZD9668 Compared to AZD9668 Tablets and to Further Investigate the Safety and Tolerability of AZD9668 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 18 May 2017
At a glance
- Drugs AZD 9668 (Primary)
- Indications Bronchiectasis; Chronic obstructive pulmonary disease; Cystic fibrosis
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 06 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Dec 2009 New trial record